Biolex Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1997-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.biolex.com
Clinical Trials
7
Active:4
Completed:3
Trial Phases
2 Phases
Phase 1:2
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (50.0%)Phase 2
2 (50.0%)480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV)
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2012-02-02
- Lead Sponsor
- Biolex Therapeutics, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT00953589
- Locations
- 🇧🇬
Tokuda Hospital, Sofia, Bulgaria
🇧🇬UMHAT "Alexandrovska", Sofia, Bulgaria
🇧🇬UMHAT "St Ivan Rilski", Sofia, Bulgaria
Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV
Phase 2
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2012-02-02
- Lead Sponsor
- Biolex Therapeutics, Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT00863239
- Locations
- 🇺🇸
eStudy site, Chula Vista, California, United States
🇺🇸eStudy Site, Oceanside, California, United States
🇺🇸Medical Associates Research Group, San Diego, California, United States
Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C
Phase 1
Completed
- Conditions
- Hepatitis C
- First Posted Date
- 2008-01-14
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Biolex Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT00593151
- Locations
- 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸Methodist Dallas Medical Center, Dallas, Texas, United States
🇺🇸Alamo Medical Research, San Antonio, Texas, United States
News
No news found